Analysis of circulating CD19+ tumor cells in the periphery showed that while Blinatumomab delayed tumor growth, it was unable to fully control the disease, with CD19+ cells already detectable in peripheral blood (PB) from day 48 (Figure 5C). The gene discussed is CD19; the disease is neoplasm.